Full Transcript Introduction and Speaker Background 0:08 Hello, 0:08 I'm Doctor Joseph Rafael, your host of the Telomere Summit. 0:12 Today I'm very pleased to be talking to Doctor Gordon Louse. 0:16 If you're interested in telomere biology and its clinical applications, 0:19 I guarantee you will be fascinated to hear about psychobiology and specifically how 0:23 IG glycans can help you take better care of your patients aging processes. 0:28 Welcome, Gordon. 0:30 Thank you for the intro, for the invitation. 0:33 Pleasure to be here. 0:34 I'm looking forward to talking to you. 0:35 Doctor louse is a professor of biochemistry and molecular biology 0:39 at the University of Zagreb and director of the National Center 0:41 of Scientific Excellence in Personalized Health Care. 0:45 Honorary professor at the University of Edinburgh and the King's College London. 0:48 And member of the Johns Hopkins Society of Scholars. 0:51 In 2017, he initiated the launch of the human 0:53 like project and is one of its two co-directors. 0:57 His research team is pioneering high throughput glycolytic analysis 1:00 and application of glycan biomarkers in the field of precision medicine 1:04 by combining iconic data with extensive genetic, epigenetic, 1:08 and biochemical and physiological data in a systems biology approach. 1:12 They are trying to understand the role of glycans in normal physiology and disease. 1:16 Professor glycan, sorry. 1:18 We see your profession. Glycan. 1:19 Professor Louse, has authored over 200 research 1:23 articles that are cited over 5000 times. 1:26 He he was pi and co-pi for four NIH and two FP, 1:31 six seven FP7 and six H 2020 1:35 and three DSI funded projects and coordinated five of them in 2007. 1:39 He founded, you know, a biotech company 1:42 that is currently the global leader in high throughput glaucoma. 1:46 Welcome again, Group. 1:48 I'd like to 1:49 start this conversation by having you introduce to our listeners 1:53 some basic psychobiology, because they may not be familiar with it, 1:55 as I wasn't until about a year and a half ago. 1:59 So glycosylation is the most elaborate 2:03 and the most abundant post-translational modification. 2:05 So glycans, chemical structures, complex soluble saturates 2:10 which are being added to proteins, post-translational. 2:14 So they're not encoded in a single gene like the polypeptide, 2:18 but they're encoded in the network of hundreds of genes 2:22 which enable proteins to like human bodies to acquire novel functions, 2:28 even after the gene for a specific immunoglobulin has already been defined. 2:34 And, I work in the field of glycan biology for, I think, over 30 years now. 2:39 And we established 2:42 a field called high throughput electronics, where we started to analyze 2:46 thousands and thousands of, glycans from different people. 2:50 So kind of, similar to personalized medicine. 2:53 We are trying to do personalized comics, and we already 2:57 analyzed over 150,000 people. 3:00 And by analyzing so many people from many really well-characterized cohorts
What Glycosylation Is and Why It Matters 3:06 from all around the world, we learned that glycans attach to when a global is, 3:13 highly correlated with aging. 3:16 And other people also work on you glycosylation. 3:19 And I'm going to Globulins are the the best selling drugs 3:22 in the world for a decade already. 3:25 And we know that these glycans 3:28 have many regulatory roles on immunoglobulins. 3:31 And one of these roles is the regulation of low grade chronic inflammation. 3:36 So if there is a specific type of glycans, which usually we find in young people on 3:44 immunoglobulins, these immunoglobulins actually suppress inflammation. 3:49 They do not allow this low grade chronic 3:51 inflammation to be present everywhere. 3:55 But if glycans are changed, 3:58 if different glycans added to one of global is 4:01 the pro-inflammatory glycans, which are usually shorter, 4:05 they don't have a galactose in the cell like acid on the end, 4:08 they become pro-inflammatory. 4:11 And this is something which we usually see in old people. 4:14 We see that people have a glycans which are pro-inflammatory. 4:18 So they're actually promoting low grade chronic inflammation. 4:23 And in this way they're significantly contributing to the inflammation. 4:28 So they're doing damage to the tissues 4:32 which is then manifest that that's aging. 4:35 But also it's age related diseases. 4:38 Yeah. 4:38 So it's a whole new area of biology. 4:40 That's that's that's really fascinating. 4:44 As a biomarker of aging, sort of, you know, 4:46 telomeres are a biomarker basically you have epigenetic DNA methylation. 4:49 The correlation is it sort of linear across from, you know, say 20s to 80s, 4:55 or is there kind of a, you know, an acceleration at some point? 4:59 And what's the spread on either side? 5:02 So here's of year's different it's different than men and woman. 5:06 So when you look at the men, men have more or less linear increase 5:11 in glycans from their kind of early 20s when they're the most, 5:18 suppressing inflammation 5:20 to the old age, when they're more, more pro-inflammatory. 5:23 In women, the curve is a little bit different. 5:26 So, the biggest change happened around menopause. 5:30 So before menopause, women usually 5:34 have less of these pro-inflammatory glycans than men. 5:38 But then in perimenopause it accelerates rapidly. 5:43 And they quickly catch up with men and actually go above 5:46 the men average for a short period of time. 5:49 And then they kind of kind of, look similar later. 5:54 So it's, it's different men and women and, it does change with time a lot. 6:00 And when you, when you give a like an age to, you they, 6:05 they, you have to test in your lab and say a woman is 60 years old. 6:08 Is that her glycan age against a untreated postmenopausal? 6:13 Group or. It's a guess. 6:16 So it's a 6:18 it's a, it's a, it's against no, no treatment 6:20 because that's how you and I sort of met 6:23 because I started ordering your test and we, saw that some of our patients, 6:28 particularly men and women, but had much younger glycan ages. 6:31 And everybody in my practices is on some sort of hormone optimization. 6:35 There's there's a big impact there. 6:38 We were, you know, talking about I know a lot of our listeners practice 6:41 hormone optimization and, and so talk a little bit about, 6:45 you know, that, what happens with performance 6:47 because I know there's other things that impact glycans like lifestyle, 6:51 body fat, metabolic health, hypertension, etc.. 6:55 But I think you know, one of the biggest impacts is hormones. 7:00 So our baseline is the general population. 7:03 And in the general population, a majority of people are not 7:07 doing hormonal feminization. 7:09 So I would say the baseline would be people who do not do hormone optimization. 7:16 And the the glycan age 7:20 index we have is modeled based on these thousands of people. 7:24 We did in the past. 7:26 So we kind of say your glycans look like an average 7:31 glycans of a person of 58, 75 or whatever year old. 7:37 As you mentioned, we got quite puzzled with your data. 7:42 And actually, my statisticians were initially wondering 7:46 what went wrong and why. 7:48 Why are all the the samples which we are now analyzing 7:52 coming from, from your lab so much younger 7:56 until we started talking and doing more and more people 7:59 and realized actually, that what you do in your practice is actually 8:03 making people look younger on, I would like an age test. 8:07 And here I would like to stress one very important aspect, 8:11 and this is that glycans and immunoglobulins. 8:14 And I would like an age they're not only a biomarker. 8:17 For example, if you talk about epigenetics, 8:20 methylation on a specific CPG site is just a biomarker. 8:25 We don't know anything about its function and people original. 8:30 Steve's, Steve Horwitz, epigenetic clock 8:34 is something like, I think, 373 CPG markers. 8:38 Lichens are functional effectors. 8:40 So these are molecules which either suppress 8:44 or promote inflammation. 8:46 So if somebody has more of these glycans which suppress inflammation, 8:54 we know that inflammation level will be lower. 8:57 And if there is more of these glycans which promote 8:59 inflammation, we know that they're actually promoting inflammation.
Glycan Age as a Biomarker of Aging 9:03 And now we know that this low grade chronic inflammation is behind 9:07 so many different, chronic diseases that actually we can be very confident 9:13 that having a lower glycan age is something which is good, 9:18 which is associated with a lower 9:20 risk of a disease 9:23 or a milder disease, and something and something else, 9:27 which is also very important when we look longitudinally, 9:31 glycans usually change first. 9:34 In some diseases, they change up to ten years 9:37 before the disease is actually diagnosed 9:40 because, you know, disease. 9:43 This is a name which was given by physicians 9:47 for a condition when people appear to the hospital 9:51 because something does not work, 9:53 there is pain, some organ doesn't function and then you get a disease name. 9:57 This does not happen overnight. 9:59 This is a long process where the body's first 10:02 trying to compensating to compensate for a problem. 10:05 And then when all the compensatory mechanisms fail, there is disease and 10:12 synovial 10:12 globulins are one of the early things which happen. 10:15 So before you get ill, your immunoglobulins become pro-inflammatory. 10:20 They start to do damage 10:23 and while we haven't proven in humans, 10:26 we have some evidence in animals that if you improve glycans, 10:30 disease does not happen for humans and only have correlation. 10:34 Glycans change first and then the disease appear. 10:37 Which specific diseases are you're talking about? 10:39 Just, So so we have one study where we have shown 10:45 that by preventing these bad 10:49 glycans, you can prevent hypertension. 10:52 And this was done on mice. 10:53 Mice were fed, high fat diet 10:56 and on high fat diet they became fat and they developed hypertension 11:00 and their immunoglobulins were high positive. 11:04 Later they had less sialic acid, which is this Yankee venom. 11:08 And when mice were fed and something 11:12 which is the precursor for cyclic acid, 11:15 their immunoglobulin glycans 11:18 preserved this good glycosylation. 11:21 So they had young immunoglobulins. 11:25 Of course, they got fat on a high fat diet, 11:28 but they did not develop hypertension. 11:30 So actually by by by preventing 11:34 aging of immunoglobulin glycans, 11:37 it's possible to save mice, obese 11:40 mice from developing, hypertension for humans. 11:44 We do not know. 11:45 We did study a small cohort of healthy people 11:49 where we did not see a big change after taking menos amine, 11:53 but we do not know whether actually in obese people 11:58 taking menos I mean would improve glycosylation and 12:01 and contribute to the decrease in hypertension. 12:04 Something what we published only a couple of days ago 12:07 is that we were tracking, 12:10 2000 twins in UK for 20 years. 12:15 And then we have shown in this study 12:18 that, and actually there was a replication cohort in Germany that 12:24 glycans today are predictive of hypertension in the future. So 12:28 maybe this could also work in, in humans that if you improve 12:34 your glycans, 12:36 you will not develop hypertension in the future. 12:39 And, well, that's that's really fascinating. 12:42 Would that that I would imagine that would 12:45 probably also, extend to atherosclerosis. 12:48 And you looked at, and those mouse models of atherosclerosis as well, 12:52 particularly with the high fat diet. 12:54 I wonder whether there's, an impact there, 12:56 because particularly women, you see women going through menopause, 12:59 they're very well protected. 13:00 And we you know, we thought it was from the estrogen before menopause. 13:03 That, from getting atherosclerosis. 13:07 And then afterwards, the corner calcium 13:09 score start going up the carotid into the medial thickness goes up 13:11 and their events start going up. 13:12 The catch up with men relatively rapidly. 13:15 And I suppose that could be because 13:18 of the change in the glycans that occurs with the loss of estrogen. 13:21 And do we have any. Go ahead. 13:23 So, of course, 13:24 hypertension and all cardiovascular or all other kinds of 13:29 metabolic disease are very complex and they're very different 13:32 in different individuals. So we cannot generalize. 13:35 But I guess that this is one of the important mechanisms 13:38 because we know that inflammation is important. 13:41 We know that these old items are pro-inflammatory. 13:46 For example, in woman, we definitely know that estrogen 13:50 actually in both women and men, estrogen 13:52 is improving the egg like, composition. 13:55 We had one, proper, randomized, placebo 14:00 controlled trial where the menopause was chemically induced. 14:04 And then in the placebo group,
Hormones, Menopause, and Estrogen Effects 14:07 we saw a huge increase in, like, an age, 14:10 I think average was nine years and six months. 14:12 There was some woman who aged for 20 plus years in the few months 14:16 while in, estrogen, 14:21 groups of people where the estrogen was returned 14:24 with, with this, estrogen patch, there was no change in the glycan age. 14:28 So definitely estrogen is causative. 14:32 And, it does improve glycans. 14:34 And in interestingly, in men, if you give testosterone 14:38 like an age old, it improves. 14:40 But if you block aromatase, the enzyme which converts 14:44 testosterone to estrogen, there is no effect. 14:47 So it's actually estrogen which is improving energy like in men too. 14:52 Yeah. 14:52 And that's a very, you know, when I heard that I had always been 14:55 cautious with arithmetics or any anastrozole, any, 14:59 aromatase inhibitors in my practice, but other, practitioners, 15:03 I think they use it because they think estrogen is a bad thing in men. 15:07 But a certain level of estrogen is very important. 15:08 And here's, you know, another reason why you don't want to block it down too much, 15:12 because you're going to lose that benefit. 15:13 And and the benefit is, just turning to men for a second. 15:16 The benefit is really quite significant. 15:18 The average glycan age in my practice on men 15:22 that are on testosterone replacement therapy with, you know, good 15:25 youthful levels is 25 years younger than their chronological age. 15:30 And, you know, that is it's a fit group for sure. 15:34 I mean, they're working out, but, we see a change when they come 15:37 in, even if they are fit and with a low testosterone levels. 15:41 So, you know, that's we're up to about 160, 270 patients. 15:46 Now we're looking at 15:47 we try to see, you know, what other factors might be involved there. 15:50 But it's interesting to me that it's even more in men. 15:54 I don't know if you saw that in your study. 15:56 Whether there was a, a change, change, a bigger change. 15:59 And like an age in men 16:00 when they, knocked out the estrogen, from the testosterone. 16:05 So definitely if the. 16:08 So this was not it was a different study. 16:11 And in that study, we did not look like an age. 16:14 Typically it was a little bit older study when the glycan age was not. 16:18 We're not able to measure it then. 16:20 But what we did see is that this change from young to old, like, 16:26 did happen if the other the hormones were blocked 16:30 and it did happen 16:31 is the conversion of testosterone to estrogen was blocked. 16:35 But if the testosterone was returned and it was 16:38 and there was no inhibition of this, aromatase, 16:43 then the glycan age did not change, not look like initially the 16:46 the IG glycans did not change in the direction of older glycan age. 16:51 So, definitely, I think just blocking the conversion 16:55 of testosterone to estrogen would not be beneficial in, in, in respect 17:01 of inflammation and immunoglobulin like, affecting inflammation. 17:06 Yeah. 17:06 I mean, I think that's 17:07 and we know in other things for bone health and for arterial health 17:11 that that's it's important, to maintain a certain level of, of, of estrogen. 17:16 I always tell my patients, 17:17 when women come in with post-menopausal women that, 17:20 you know, their husbands have 3 to 4 times 17:22 the amount of estrogen circulating in their blood, than than they do. 17:25 And that's, you know, time to get back to at least a man's level of estrogen. 17:29 So, I mean, I think that the, this test that you have available, 17:34 which, by the way, is really great because it's a blood 17:38 spot, can be sent to the patient and, and readily done. 17:42 Is, I think, going to transform menopausal and, and or causal medicines 17:47 a certain degree. 17:48 I know you're working with Louise Nissen in, in the UK. 17:51 Looking at you're doing a trial, looking at, the effect 17:55 of, of estrogen replacement therapy or on replacement therapy on glycans. 17:59 You know, it seems to me that all the benefits 18:03 that we thought estrogen had prior to the Women's Health Initiative, 18:08 you know, 18:08 have been turned around with a, a reanalysis of that data, 18:12 looking at it with a better lens and the timing hypothesis, etc. 18:17 but having this tool to know whether 18:20 or not a woman has gotten back her 18:23 anti-inflammatory glycans, I think, would be pretty revolutionary. 18:28 You're looking at it as a marker for perimenopause and, 18:32 and for, for even potentially the adequacy of therapy in menopause. 18:36 So we haven't published anything on that yet. 18:39 We only have this study, which was the menopause. 18:42 Was the chemical induced, but we have some initial data. 18:45 And something which seems fascinating to me is that, 18:49 glycan age can deteriorate 18:53 rapidly in women in their menopause, 18:56 especially in women who were, who had very good like an age before. 19:01 So we have seen, patients 19:04 changing for 30 years, within a year. 19:07 And interested only glycans change 19:11 before any other symptoms appear. 19:14 So we had a situation where women were shocked 19:17 with what happened to their glycan age, and they said that they have no symptoms, 19:20 they have no problems. Everything is okay. 19:23 And then a couple of months later, 19:26 all the symptoms of menopause appeared. 19:30 And this is why, the reason why we see that 19:33 is that, estrogen really directly regulates glycosylation, 19:39 and it regulates it in a kind of a long term manner. 19:43 Because IgG we measure today is made in the last couple of weeks. 19:49 So all the alterations in the hormone levels 19:51 which happen at that period are kind of integrated in the glycan. 19:55 So you can still have spikes of hormones. 19:57 You can keep other things functioning. 20:00 But the glycan age 20:02 in glycans we will be changed. 20:05 And I think this is very similar to way 20:09 HbA one C the Glycated hemoglobin 20:13 can be used to track the average level of glucose. 20:16 In the past weeks. 20:19 In the same way, like an H 20:22 can be used to track the level of estrogen. 20:26 In the past weeks. 20:28 And so it could be a very early warning signal 20:32 that somebody that entering the the menopause. 20:35 And of course, we still have to do a lot of research. 20:38 We have no idea whether it's better to start therapy early, 20:42 whether you get the same results after a couple of months without hormones. 20:46 There are many questions which we are interested to address, 20:49 and we are trying to do as as properly design studies as possible. 20:54 And of course, we are extremely interested to collaborate, especially 20:57 if somebody already has, you know, hundreds of samples in the fridge. 21:02 We can do a very quick study to see what happens with 21:06 with, IG life insulation in women in this very sensitive period 21:12 where there are so many changes happening in the body. 21:15 So, I'm just 21:18 curious about the change of if you get a big 21:22 increasing like an age at the loss of estrogen. 21:25 I don't know if you've looked at this, but pre puberty, does a young girl get, 21:31 a change in her IG like oscillation 21:34 when she goes into, into menarche? 21:38 So we, you know, working with kids is a little bit more difficult. 21:42 So we haven't done so many children, 21:45 but we have done a couple of hundred. 21:48 And for example, boys and girls look very similar before puberty. 21:52 Right. 21:53 And then we with the onset of puberty, girls start to change very rapidly. 21:58 And it's a little bit strange because actually kids, despite, 22:04 before they develop this, hormonal, 22:08 status of an adult actually have very pro-inflammatory gene. 22:13 So, young kids look like much 22:16 older adults in their IG, like, composition. 22:20 And, and we know from experience their kids are actually extremely 22:24 pro-inflammatory. 22:25 Their, their immune response can be very explosive 22:29 when there is some kind of, inflammation going on. 22:32 And then this is suppressed with the hormones for the reproductive 22:36 period of their lives, and then they go back as old 22:40 and older individuals to be more, more pro-inflammatory. 22:44 So, I actually very enthusiastic about what you do with the hormone optimization. 22:49 And I think this could actually help. 22:52 Alleviate many problems related to inflammation, 22:56 which is linked to all these, diseases which are now 23:00 a burden for the planet because we all getting old. 23:04 Yeah. I mean, we, 23:07 we see with testosterone, for instance, or, 23:09 and as well with, with estrogen that things like insulin sensitivity improve. 23:13 You know, you lose body fat. 23:16 And so all these metabolic changes that occur, you know, 23:19 there may be, some kind of a, 23:23 mechanism through the IG glycans, which is 23:26 how this is taking place. 23:28 So, you know, I think it's a re validating 23:31 this concept that, you know, humans, both males and females, 23:35 need a certain level of, of estrogen, to, to have a, 23:40 an optimal aging, particularly from an inflammatory standpoint. 23:44 Are there any other 23:46 genetic factors that, figure into this? 23:48 I mean, we've been talking a lot about hormones. 23:50 I mean, is is there, what percent of it is heritable, you know, 23:55 so we did a number of heritability studies. 23:59 And for the different glycans in aged, you like them who are heritability 24:03 is between 30 and 75%. 24:08 So an average we can say maybe approximately half of the composition
Lifestyle, Exercise, and Weight Effects 24:12 is genetic, meaning that, if your parents have kind of older, 24:16 like, all the time, you will be in that direction. 24:20 Maybe approximately 50% of the variation could be explained by genes. 24:25 And it's extremely complex network. 24:27 We have already mapped over 40 genes 24:30 which work together to regulate that glycosylation. 24:33 And they're not enzymes which actually put the glycans there. 24:36 The different genes which regulate the the immune system. 24:41 And another very important aspect 24:43 is, lifestyle and environment. 24:47 Obesity is a very strong factor. So, 24:52 with the 24:52 increase in the body weight, glycans age faster. 24:56 And we also did on these same 2000 people, which were tracked 25:01 three times in, which were analyzed three times over 20 years. 25:05 We have noticed that. 25:07 And these are mostly woman. 25:08 They're from the twins UK cohort, which are mostly female. 25:12 And we noticed that the women which were gaining 25:15 weight over these time points, they were aging faster 25:21 than the women who were losing weight or not changing their weight. 25:25 So by gaining weight, 25:27 you actually accelerate this inflammatory process. 25:30 And then by losing weight, you can improve it. 25:33 So one of the easy things which we all can do 25:37 is just take care of this extra body fat, which we don't need. 25:41 And this is also improving this as you like. 25:44 But interestingly, there does not seem to be a magic diet. 25:49 We did a study of 2000 people on five different diets, 25:53 including the 25:55 high glycemic index one and, and each of the diets 26:00 were beneficial for some people, 26:03 and they were very bad for other people. 26:05 So I did like them. 26:07 We're changing in both directions on all types of that. 26:11 It's actually one has to try what works for him or her. 26:17 And the same goes for exercise. 26:19 So, we all tend to believe that, you know, eat so much, 26:24 you just have to exercise a bit more and then you're fine. 26:27 And this maybe works when your kids or when you are young. 26:30 But as you are getting older, you cannot without what you eat. 26:35 And people who overtrain 26:38 tend to get also pro-inflammatory and get very bad, like an inch. 26:42 For example, 26:43 initially we were thinking that the gyms would be a good place to start working. 26:47 We looked like an age and helping people improve like energy in the gym. 26:51 But then it turned out that most of the personal trainers 26:54 and most of the people who are fanatic about going to the gym actually got worse. 26:59 And if you take a middle aged people and try to work 27:04 with them intensively, they also get worse. 27:07 So yes, exercise is important, 27:10 but there has to be a sufficient relaxation time 27:13 and there has to be sufficient time to compensate for all this 27:17 pro-inflammatory aspects of, of exercise, because, you know, 27:22 you do need some level of inflammation to start your muscle expanding. 27:27 But if you do this in a, in a, in a chronic way, 27:31 then of course, you increase this low grade chronic inflammation, which is bad. 27:35 So we are now trying also we are doing several studies to try to find, 27:39 optimal way of exercising 27:43 and relaxation, which would help you to improve your glycans. 27:48 So it's 27:48 a very interesting field of study to. 27:53 This is probably, sorry. 27:56 Yeah. 27:56 I mean, I have ultra endurance athletes in my, in my practice 28:00 and then even, like, crossfitters and people who are really going at it and, 28:04 and one could use it as almost a biological hoop. 28:07 You're familiar 28:08 with the hoop device, and where it tells you about the strain on your body. 28:12 This is sort of a molecular, 28:14 sort of integrator of it over a longer period of time. 28:18 Like you said, it's 3 to 6 weeks for the glycans to change into their particular 28:23 if they're, you know, premenopausal and you have relatively younger, 28:27 you know, 30s or 40s, if their glycans are a lot higher 28:31 and they're 28:31 they don't have to carry a lot of body fat and they're probably overtraining. 28:34 And it's a good way, I'm thinking it be a good way to tell them, 28:38 you know, maybe you need to put in some more days of rest. 28:40 And we could track it to see whether you're like, an age is responding to that. 28:45 I think that could be another fantastic way. 28:47 And people who not who are not even on hormone 28:48 optimization, to see whether or not this is the opposite problem. 28:53 People aren't aren't exercising enough and are overweight and are eating too much. 28:57 You do have the other side of it. 28:58 I mean, I'd love to see people that 29:01 sort of do Ironman triathlons and, you know, I sports one. 29:04 I did one a week, 29:06 for, for a year around the globe. 29:08 I mean, what is glycans look like? 29:09 This kind of stuff is probably not good for you in the long run. 29:12 And it's it's good information to tell patients. 29:14 You know, this is not surprising because the professional athletes 29:18 are old in their 30s now. They. 29:21 And you cannot put too much stress on your 29:26 on your body and do not expect to have consequences. 29:29 And one thing which I forgot to mention 29:31 also the psychological stress plays a game, plays a role. 29:34 So it's also important to have, 29:39 psychological relaxation, to feel good, 29:42 and to have sufficient in our moment of exercise, 29:45 but not too much healthy food, but not too much. 29:50 And then things are in kind of, balance, 29:53 which is, you know, it's, it's there's no magic. 29:57 We all know what is good and what is not good. 30:00 The problem is that we all think that we are fine. 30:06 Now, you look yourself in the mirror. 30:07 You are same as yesterday. 30:09 You don't see anything. 30:10 And unless you have some kind of pain and even you have, 30:13 you can take a pill and the pain goes away and you just go on and go on and go on. 30:18 But there is the wear and tear in your body which you cannot see. 30:22 And then usually, at least for men, you know, we stop 30:26 after the first heart attack or stroke, but then it's often too late. 30:31 So ideally I want to get an early warning signal 30:36 to tell me, you know, you are not going in the right direction. 30:40 I mean, I don't want to wait for 20 years to get the feedback right. 30:45 I want to get feedback as soon as possible. 30:47 So if I start losing my weight, 30:51 I want to see an effect in a couple of months. 30:53 And if it's not working, then I can try something else. 30:56 And this is where I see a huge potential of this test, 31:00 which we have developed, is that to help people 31:04 motivate themselves to do a difficult decision, 31:07 because I was keeping that extra cookie is a difficult decision. 31:11 Skipping that extra beer or whatever. 31:15 It's a difficult decision and people need rewards. 31:18 And if you get a reward in the next after 31:21 few months, you see your glycan age is going down. 31:24 I think it can help people. 31:26 That's kind of a idea. 31:29 Yeah. No. Of course. 31:29 Did you see any because I know people practices. 31:33 Do you see any relationship between intermittent fasting and, like an age? 31:38 Or is that going to be correlated to if there's weight loss or not? 31:42 So we, we haven't done 31:44 a proper study of intermittent fasting. 31:47 My guess is that it would be beneficial. 31:51 At least we know that intermittent fasting 31:53 is a good for your microbiome then your microbiome. 31:57 Because know 31:58 the problem with eating all the time is that in your gut there is always food. 32:02 And then the most aggressive bacteria grow, 32:05 while when when your digestive tract is empty, 32:09 then only bugs which can attach to your, gut and to kill you 32:15 and actually graze on the glycol calyx survive. 32:19 And this is our evolutionary symbiosis between the bacteria we like 32:24 and our, glycol colleagues, which is feeding them. 32:28 And if you do intermittent fasting, then you have this selection periods 32:32 where you get rid 32:33 of all the aggressive bacteria and only the ones you like to keep them. 32:37 And we know if you improve your microbiome, you will improve your glycans. 32:42 So we had several studies with the fecal microbiome transplant. 32:46 And yes, improving the microbiome improves the glycol.
Disease Prediction, Telomeres, and COVID 32:49 Well I would guess that the properly executed intermittent fasting 32:55 after some period would improve the, the, 32:58 the egg like but we haven't done a study yet. 33:01 So if, if you know somebody who might have some samples in the fridge, 33:05 more than happy to look at it, I don't know, Walter Longo might have some, he's 33:10 done the, the sort of fast mimicking diet, and he's done a lot of research on that. 33:15 Is a possible person for that. 33:16 I don't I don't have, anybody else that I know that has samples. 33:21 You know, you mentioned hormones. 33:23 You mentioned, stress, but psychological and physical 33:26 as things that affect the ECG, like, 33:31 those are all sort of same sorts of things 33:33 that affect telomere length and telomerase activation. 33:36 I'm wondering I did a quick look and I didn't see anything much. 33:40 Is there any research on the relationship between 33:44 tumor biology and glycan biology? 33:47 So we did look in a couple of cohorts. 33:52 We haven't seen a huge, correlation. 33:56 So I think one of the key problems with the telomeres is that, first 34:02 how you measured them, some of the cohorts have 34:05 telomere measurement, which is not extremely reproducible. 34:09 And the second thing is it's heavily biased 34:12 with, with the composition of the the cells in, in the blood. 34:17 So it's 34:20 you know, 34:20 telomeres are a fantastic biomarker for an individual cell, 34:25 but on an organism level it's a little bit more complicated. 34:30 So guess I'm, we were talking to Bill 34:33 Andrews a couple of times to try to do something together with him. 34:36 He's also very enthusiastic about it, but we haven't done anything yet. 34:40 So eventually, as we will look, whether the same intervention 34:45 has the beneficial effects for both telomeres and the glycans. 34:49 Yeah. 34:49 We just recently published a fact of 65 34:52 on, immuno senescence, 34:55 Cd28 negative cells, and there was a reduction in them. 34:58 Presumably we think through telomerase activation 35:02 and sort of send a lytic like effect, although, 35:06 we don't know whether the cells went away or whether 35:08 they were just turned back into C 28 positive cells. 35:11 But, you know, the senescence, immuno senescence, it takes place is, 35:16 I guess, tracking a long or is there some relationship between that 35:19 and the like a I think like an, change so that it becomes more inflammatory. 35:24 I mean, we are 35:25 we are now, you know, collecting the samples of patients who have we have, 35:29 you know, lymphocyte subsets with the senescent cells, the telomeres 35:32 and the like. 35:33 An agent will see if there's something there as our sample size gets larger. 35:36 But it's not, you know, of course, a controlled trial. 35:38 And I wonder whether there's any, 35:40 any thought about the that sort of correlation 35:42 between the senescence that we know goes up because of replicative senescence, 35:46 the loss of telomere length, and the change 35:50 in the glycans, maybe in the I mean, this is a post-translational thing. 35:53 So it's not going to be in the B cell senescent cells. 35:56 It's it's whatever 35:58 whatever pathways are affecting that 36:01 glycosylation of of of the, of the ATG. 36:04 And whether or not 36:06 I think what we know that when you have cells in culture 36:10 and where they're, when they're getting older, 36:13 they change glycosylation of immunoglobulins, they produce. 36:17 So definitely they're I would expect to see an effect. 36:21 But you know, cell culture and and the human body, 36:25 they're two very different things. 36:27 And you know, we cannot look you know, we are a complex machines. 36:32 We have evolved for billions of years to compensate 36:35 for all type of problems, to fight all possible threats. 36:39 And I think one of the most well, we have two very complicated systems. 36:44 One is of course, our brain, 36:46 which is immensely complicated, and the other one is our immune system. 36:50 Our immune system is keeping us alive against all these 36:53 crazy bugs which mutate like, like like, you know, crazy. 36:57 They mutate all the time. 36:58 And we still survive. 36:59 So this is a very intricate and a complicated mechanism which has to balance. 37:07 Fight against 37:08 infectious agents against on the other side, 37:11 there are tumors which can acquire the mutations cells. 37:15 So it's, you know, I think this is all very complicated. 37:18 We cannot simplify it too much, I think. 37:22 Yes, glycans and senescence and telomeres are correlated in a way, 37:28 but I think there's still a separate aspects of this whole process. 37:32 So we have to look at telomeres. 37:33 We have to look at we have to look at glycans 37:37 and then try to integrate all these data. 37:40 And you get more information. 37:41 You know they 37:42 they measure different things and they're all important processes. 37:44 And what's interesting is that there are ways to impact them 37:48 different ways or different systems. 37:49 And I mean, I think you're like an age 37:53 marker is great because, 37:56 you know, even if you have a good lab, like repeat diagnostics doing, 38:00 the telomere length and they can do also the neutrophils, which are not, 38:04 you know, subject to changes because they're, they're really reflecting 38:08 the bone marrow stem cell. 38:10 It's a longer process with glycans. 38:12 It's I, I thought it was three months or you're saying really 3 to 4 weeks, 38:17 you can get a significant change in the glycans. 38:19 How often do you think people should test to see, you know, what the what 38:23 ending depends depending what happens. 38:26 So if there is no major change in a body 38:31 it's months. 38:32 They don't change very rapidly. 38:34 So example now we were doing a lot of studies on Covid in the last year. 38:38 And people who had, severe Covid, 38:42 we saw a lot of changes in their attitude, 38:44 like, in a matter of two weeks. 38:47 So they would gain, I don't know, 38:50 ten, 15, 20 years in a couple of weeks. 38:53 And it was the worse. 38:54 So people who died actually had the most significant changes and still unpublished. 38:58 But this is what we have seen so far. 39:01 So, when there is, rapid 39:04 change in a body like a infection and maybe hormones, 39:09 so what we are doing now is just looking how quickly 39:12 the glycans would change after the start of the hormone replacement therapy. 39:17 Then it could be faster. 39:19 So for example, we have a cohort of human which we are tracking 39:22 now every two weeks to see how rapidly does it change. 39:26 But in things like a weight loss or exercise, 39:29 usually we don't see anything before two months. 39:32 And I think you also mentioned, when we talked before, 39:35 or maybe it was in another with the Lena that there isn't that much change 39:39 across the menstrual cycle. 39:40 So if you have a premenopausal woman, you don't necessarily have to to, to 39:44 do your test at the same time of the cycle. 39:47 Is that correct? 39:48 For majority of women there are no huge change. 39:52 It's maybe a few percent. 39:54 We have seen examples of some women 39:58 where the changes were more, more, significant. 40:02 So it would be better to try to kind of match 40:07 the, the, the similar phase of a cycle. 40:11 But if it's a longer term, it's not so important. 40:14 But oh, okay. 40:16 So maybe try to do the luteal phase or the follicular phase 40:20 and just keep that same one. 40:21 It doesn't matter necessarily which, which one. 40:23 And speaking of hormones, are there any other hormones that impact 40:27 glycans that you think's, significantly or is there any research on Abby? 40:30 I mean, I have quite a few patients on growth hormone IGF one increases. 40:35 I don't know. 40:36 You know, I haven't seen a signal yet, but we don't know cortisol, 40:41 because cortisol is sort of the inflammatory, one. 40:45 We haven't seen huge effects of dexamethasone. 40:49 Really? 40:49 Yeah. 40:50 So dexamethasone doesn't do much in a short term. 40:53 So in the long term, of course it does. 40:56 But, for example, we know that, 40:59 okay, TNF is not a hormone, but it's important signaling mechanism. 41:03 So if there are if people are taking monoclonal drugs against TNF, 41:08 we can see a very strong effects in some people. 41:12 In some people not so strong. 41:14 So, I would guess that 41:16 many of the immunomodulatory 41:19 monoclonal could have a strong impact, 41:23 but these are not things that people take, regularly deserve. 41:27 Right. That's for different conditions. 41:30 So, you know, the thing is, glycans that very novel. 41:34 So the technology to measure them in high throughput is here 41:36 only for maybe a decade. 41:39 We managed to develop this, dried blood stain testing 41:43 only two years ago because previously we had to have a frozen plasma. 41:47 And this is a logistical complicated. 41:50 If you collect a sample and then you have to freeze it 41:52 and ship it frozen, it's complicated. 41:55 So once we started working with the dried blood stains, 41:58 everything became much simpler. 42:00 You can actually ship it anywhere in the world. 42:02 People can collect, sample and mail it back. 42:04 And it's okay. 42:05 We can we can work with with the data generated from the samples. 42:10 So it's, still not so many labs doing that. 42:14 There are actually there there are over 100 labs in the world 42:17 which can analyze egg glycosylation, 42:20 but, not so many of them do it in the high throughput. 42:24 So this is 42:25 why there's no, human not huge amount of data. 42:29 It's more and more people working. 42:31 We even have it the thing called the Human Glycogen Project, 42:34 where we are trying to integrate our activities globally, 42:37 but we still have to learn a lot because this is a very complicated 42:42 part of biology and still not so many people working. 42:46 And interestingly, even at the beginning of this pandemic, the director of NIH 42:50 was writing a blog about the S glycoprotein without a single glycan. 42:55 He just showed the polypeptide part. 42:57 Well, there's more glycan on a surface than a peptide. 43:00 And then just after that, people started thinking 43:04 and saying, wow, well, there are so many glycans on this virus. 43:07 What are these glycans doing? 43:10 And now we know that the glycans are very important, that they're integral 43:12 part of not only SARS-CoV-2 but all other viruses. 43:17 So, you know, there will be more and more glycan work in the future. 43:20 I'm very positive about that. 43:23 And I know you're a very busy man, but I just want to ask one last, 43:26 one last question with regard to Covid, you brought it up in terms of testing. 43:31 If a patient has 43:32 had Covid recently, you would probably expect 43:36 their glycan age to be older, I guess, and maybe take that into account. 43:40 How long would you wait the three months if if the Covid was mild, 43:44 we don't see much changes. 43:46 So, symptomatic Covid, nearly nothing, mild Covid, 43:49 nearly nothing, severe Covid. 43:52 Yes, it can be over a decade and it can take months 43:58 for this to come back to the normal level. 44:01 But it's, if it's not, 44:03 you know, when I say severe, I mean, hospitalized in intensive care. 44:09 So even even just hospitalized means moderate, not severe. 44:13 So for the majority of people, I would not expect to see a huge changes 44:18 in how about after the vaccination? 44:19 Do you have any data on that? 44:21 There is yes we have. 44:22 We looked at some cohorts of people who were vaccinated. 44:25 We don't see any change. 44:27 So that prediction does not induce a change. 44:31 Well, I 44:32 mean, I know that you, are on the case, and I appreciate 44:36 your speaking to me, and I, I know you have to get to to your family. 44:39 As always. Great. Great talking to you. 44:42 Any last words you have to say to our listeners? 44:46 It was pleasure chatting with you. 44:48 And it's a pleasure to work together with you, because we are learning so much 44:51 from your experience and how you can actually improve people. 44:57 And yeah, eventually I have to try something of myself. 45:01 But also knowing you. Come on over. Yeah. 45:04 It's. Yeah. 45:04 I mean, it's great to work, with, you know, researchers and, 45:09 and sort of put the clinical 45:10 and the research and research together to sort of move things along more rapidly. 45:14 You know, I'm just very pleased to be working with you and, like a huge 45:18 thank you very much, Gordon. Thank you. 45:23 For.
Comments